List of Excipients in Branded Drug OXYGEN HELIUM MIXTURE 20/80

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
AGL Inhalation Therapy Co	OXYGEN HELIUM MIXTURE 20/80	oxygen helium mixture 20/80	17575-192	HELIUM

Oxygen Helium Mixture 20/80: Excipient Strategy, Regulatory Status, Patent Risk, and Commercial Opportunities

Last updated: August 14, 2026

Oxygen helium mixture 20/80, commonly called 20/80 heliox, is a medical gas mixture containing 20% oxygen and 80% helium. It is not a conventional pharmaceutical dosage form and does not use excipients in the tablet, injectable, or formulation sense. Commercial value is concentrated in gas quality, blending accuracy, cylinders, valves, delivery systems, clinical protocols, and distribution reliability.

The mixture has limited composition-based exclusivity potential. Its commercial protection is more likely to come from manufacturing controls, container-closure systems, proprietary delivery devices, service contracts, trademarks, and clinical-use protocols than from a patent covering the gas composition itself.

What is oxygen helium mixture 20/80?

Oxygen helium mixture 20/80 is a respiratory gas containing:

Component	Concentration
Oxygen	20%
Helium	80%
Other components	Normally controlled as impurities

The mixture is slightly hypoxic relative to atmospheric air, which contains approximately 20.9% oxygen. Helium has substantially lower density than nitrogen. When substituted for nitrogen in an oxygen-containing gas, it can reduce turbulent airflow resistance through narrowed airways and respiratory equipment.

Heliox has been used as an adjunct in conditions involving upper-airway obstruction, severe bronchospasm, airway edema, and difficult ventilation. Clinical value depends on the indication, oxygen requirement, delivery system, and patient condition. The 20/80 mixture has a lower oxygen concentration than commonly used 70/30 or 80/20 heliox products, so its use requires oxygen monitoring and clinical control.

Is 20/80 heliox a pharmaceutical drug or medical gas?

20/80 heliox is best analyzed as a medical gas rather than as a conventional pharmaceutical drug. In the United States, medical gases are regulated as drugs when they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease. FDA regulations address medical-gas production, labeling, current good manufacturing practice, and certification requirements under the Federal Food, Drug, and Cosmetic Act and related regulations.[1]

The regulatory classification depends on:

• Intended medical use
• Labeling claims
• Manufacturing and filling controls
• Gas identity and concentration
• Container and valve configuration
• Distribution pathway
• Whether the product is sold as a finished medical gas or as an industrial gas

The product should not be treated as an excipient-containing formulation. Oxygen and helium are the active gas components. The cylinder, valve, regulator, tubing, humidifier, and delivery apparatus are product-contact or delivery components, not excipients.

What is the FDA regulatory status of oxygen helium mixture 20/80?

There is no general basis to assume that every 20/80 helium-oxygen blend has a single FDA-approved product status. FDA status depends on the specific manufacturer, National Drug Code, labeling, manufacturing site, and intended use.

Medical-gas companies generally must address:

1. Drug establishment registration.
2. Product listing.
3. Current good manufacturing practice compliance.
4. Identity and strength testing.
5. Cylinder filling and segregation controls.
6. Labeling and storage requirements.
7. Prescription or professional-use controls where applicable.
8. Medical-gas certification requirements under FDA rules.

FDA’s medical-gas framework distinguishes between approved medical gases and gases produced for industrial, laboratory, or other nonmedical applications. A product marketed for respiratory treatment can face drug-regulatory requirements even if its ingredients are simple gases.[1]

What is the Orange Book status of 20/80 heliox?

The Orange Book is principally used for FDA-approved drug products with therapeutic-equivalence information and listed patents or exclusivity data. A commercial 20/80 heliox product may not have the same Orange Book profile as a conventional small-molecule drug.

The practical conclusion is:

• Orange Book patent-listing value is likely limited.
• Product-specific listing must be verified by NDC and FDA approval records.
• Composition-based Paragraph IV risk is unlikely to be the central market issue.
• Device, manufacturing, labeling, and supply-chain rights may have greater commercial relevance.

An Orange Book search should distinguish oxygen products, helium products, premixed heliox products, and delivery-device products rather than treating all medical gases as one category.[2]

What is the excipient strategy for oxygen helium mixture 20/80?

There is no conventional excipient strategy for the gas mixture. The relevant strategy is a formulation-adjacent product-system strategy.

Gas composition controls

The primary quality attributes are:

Quality attribute	Commercial and regulatory relevance
Oxygen concentration	Determines clinical suitability and hypoxia risk
Helium concentration	Determines density reduction and mixture identity
Homogeneity	Prevents concentration variation between fills
Moisture	Affects stability, corrosion, and downstream equipment
Hydrocarbon and particulate limits	Supports patient safety and equipment integrity
Cylinder pressure	Controls fill consistency and usable volume
Trace contaminants	Supports medical-gas quality requirements

The manufacturer should define allowable concentration ranges, sampling points, analytical methods, and release criteria. Oxygen analyzers, gas chromatography, paramagnetic analysis, or other validated methods may be used depending on the quality system and applicable compendial requirements.

Container-closure strategy

The cylinder and valve system are the most important product components. Key considerations include:

• Aluminum or steel cylinders
• Medical-gas service qualification
• Valve outlet compatibility
• Pressure regulator design
• Tamper evidence
• Residual gas controls
• Cylinder cleaning and maintenance
• Traceability by lot and fill date
• Separation of medical and industrial gas workflows

The commercial product can be differentiated through integrated cylinders, compact formats, lightweight materials, ergonomic handles, and dedicated emergency-use packaging.

Delivery-device strategy

Delivery systems can create more defensible intellectual property than the gas composition. Potential product areas include:

• Low-resistance regulators
• Flowmeters calibrated for helium-containing mixtures
• Demand valves
• Non-rebreather masks
• High-flow nasal cannula interfaces
• Ventilator-compatible mixing systems
• Pediatric and neonatal interfaces
• Transport-ready cylinder systems
• Inline oxygen and helium concentration monitoring
• Alarm systems for oxygen depletion or composition drift

Helium’s physical properties can affect flow-meter accuracy and ventilator performance. Devices designed for air or oxygen may not deliver the labeled flow rate when used with heliox. A dedicated delivery system can therefore provide a meaningful safety and performance advantage.

What formulations are protected by patents?

A 20/80 oxygen-helium composition is unlikely to provide strong modern composition-of-matter patent protection. The gases are known substances, and heliox mixtures have long-established medical and industrial uses. Any historic composition patents would require a claim-by-claim review for expiration, priority dates, prosecution history, and enforceability.

Potentially protectable subject matter includes:

• Gas blending systems
• In-line concentration monitoring
• Cylinder filling and evacuation methods
• Valve designs
• Heliox-compatible ventilators
• Flow compensation algorithms
• Delivery masks and cannulae
• Integrated humidification systems
• Closed-loop gas control
• Clinical dosing and flow protocols
• Packaging designed for emergency transport
• Manufacturing processes that reduce cross-contamination

The strongest patent opportunities are likely to involve a system claim combining the gas mixture with a delivery device, monitoring architecture, or patient-specific control algorithm.

How strong is the patent estate for 20/80 heliox?

The composition patent estate is likely weak relative to the device and delivery estate.

IP category	Expected protection potential	Commercial assessment
Oxygen-helium composition	Low	Known gases and established mixtures limit novelty
Purity specification	Low to moderate	May protect manufacturing controls but can be difficult to enforce
Cylinder and valve	Moderate	Practical design-around risk remains
Flow-control device	Moderate to high	Stronger if tied to helium-specific calibration
Closed-loop monitoring	Moderate to high	Potential value in hospitals and transport systems
Clinical method of use	Moderate	Scope depends on evidence and jurisdiction
Packaging and logistics	Low to moderate	Often better protected by know-how and contracts
Trademark and brand	High commercial utility	Important where product differentiation is limited

Patent strength should be assessed against freedom-to-operate risk for the complete product system, not merely the gas composition.

When does 20/80 heliox lose exclusivity?

There is no single universal exclusivity date for the mixture. Exclusivity may arise from separate rights:

• Regulatory exclusivity attached to a particular approved product
• Patent protection for a device or manufacturing process
• Contractual hospital or distributor arrangements
• Trademark rights
• Trade secrets involving blending, testing, or logistics
• Market access advantages from validated clinical protocols

For a conventional approved drug, FDA exclusivity may be linked to new chemical entity, clinical investigation, orphan-drug, or pediatric provisions. A premixed heliox product does not automatically qualify for those categories merely because it is packaged as a finished medical gas. Product-specific FDA records control.[2]

What generic entry risks exist for 20/80 heliox?

Generic entry risk is structurally high for the gas itself and lower for an integrated delivery platform.

Gas-only entry

A competing manufacturer may be able to produce an equivalent 20/80 mixture if it can meet:

• Required gas specifications
• FDA manufacturing requirements
• Cylinder and valve standards
• Distribution controls
• Labeling requirements
• Hospital procurement standards

The primary barriers are capital equipment, medical-gas certification, cylinder inventory, reliable helium sourcing, and local distribution.

Device-integrated entry

A device-integrated product may have stronger barriers. Competitors must address:

• Patent claims
• Human-factors testing
• Biocompatibility where relevant
• Electrical and software requirements
• Ventilator compatibility
• Clinical validation
• Hospital purchasing approvals
• Service and maintenance networks

The most credible generic-launch scenario is a regional gas supplier entering with a commodity mixture and using existing hospital contracts. The most difficult entry scenario involves a validated heliox delivery platform with monitoring, alarms, and proprietary disposables.

Which companies are positioned to compete in heliox?

Competition is likely to involve medical-gas producers, hospital gas suppliers, respiratory-device companies, and specialized distributors. Relevant global medical-gas and respiratory-care participants have included Air Liquide Healthcare, Linde, Messer, Nippon Sanso, Air Products, and regional hospital-gas suppliers. Device competition can involve companies active in ventilators, oxygen delivery, high-flow respiratory support, and gas monitoring.

The competitive advantage of each supplier depends on:

• Helium procurement capacity
• Cylinder fleet size
• Hospital distribution
• Emergency delivery capability
• Regulatory infrastructure
• Respiratory-device compatibility
• Clinical education
• Reimbursement and procurement support

The product is difficult to commercialize nationally without dependable cylinder logistics. Helium supply interruptions can create a larger commercial risk than patent competition.

What commercial opportunities exist for 20/80 heliox?

The strongest opportunities are in bundled medical-gas and respiratory-support products.

Hospital respiratory care

Hospitals may use heliox in emergency departments, intensive-care units, operating rooms, respiratory therapy departments, and transport programs. A supplier can sell the gas with:

• Dedicated regulators
• Flow-calibrated equipment
• Disposable patient interfaces
• Staff training
• Clinical protocols
• Cylinder management
• On-site inventory monitoring

Emergency medical services

Portable heliox systems can target ambulance services and critical-care transport. Product requirements include low weight, rapid deployment, durable packaging, clear labeling, and compatibility with existing oxygen equipment.

Pediatric and neonatal care

Pediatric applications may support specialized masks, cannulae, flow control, and monitoring. The commercial opportunity is device-led because clinical use requires precise oxygen control and equipment compatibility.

Home and ambulatory care

Home use is more challenging because of cylinder logistics, patient monitoring, reimbursement, and the risk of inappropriate administration. A home-care product would require strong safeguards against oxygen depletion, incorrect flow, and use with incompatible equipment.

Research and industrial crossover

Industrial and laboratory helium-oxygen products should remain segregated from medical products. Cross-market manufacturing may improve plant utilization, but medical labeling, quality systems, cylinder handling, and traceability must be maintained.

How does 20/80 heliox compare with other heliox mixtures?

Mixture	Oxygen content	Main commercial implication
20/80	20%	High helium content but limited oxygen reserve
30/70	30%	Greater oxygen support with reduced helium fraction
50/50	50%	More oxygen, less density benefit
70/30	70%	High oxygen support and lower helium benefit
80/20	80%	Oxygen-dominant formulation for selected clinical needs

A 20/80 mixture provides a high helium fraction but may be unsuitable where the patient requires substantial supplemental oxygen. The product should therefore be positioned around specific clinical and equipment conditions rather than as a universal respiratory gas.

The commercial portfolio may benefit from multiple oxygen-helium ratios, provided each ratio has a clear labeling rationale, validated delivery method, and separate quality controls.

What patent litigation affects 20/80 heliox?

There is no basis to identify a single defining patent litigation dispute for the 20/80 mixture itself. Litigation risk is more likely to arise from:

• Medical-gas manufacturing patents
• Regulator and valve patents
• Ventilator compatibility
• Respiratory-mask designs
• Gas-monitoring systems
• Trade-secret claims involving blending or filling
• Regulatory enforcement concerning medical versus industrial claims

A Paragraph IV challenge would be relevant only if a competitor filed an abbreviated application referencing a listed FDA-approved product with relevant Orange Book patents. For a commodity-like medical gas, commercial entry may occur through a separate application or product pathway rather than through a conventional Paragraph IV strategy.[2]

Are licensing deals available for 20/80 heliox?

Licensing opportunities are more likely to concern delivery technology than the gas mixture. Potential deal structures include:

• Exclusive hospital distribution
• Regional cylinder supply
• Co-branding with respiratory-device manufacturers
• Licensing of heliox-compatible flow-control technology
• Bundled sale with ventilators or high-flow systems
• Contract manufacturing and filling
• Clinical-protocol licensing
• Disposable interface supply agreements

The most valuable licensing asset would combine validated clinical performance with a device that compensates for helium-specific flow behavior. A license covering only the 20/80 composition would likely have limited bargaining power unless supported by regulatory approval, supply exclusivity, or a proprietary manufacturing process.

What manufacturing and IP barriers affect market entry?

The major barriers are operational:

1. Reliable helium supply.
2. Medical-grade oxygen sourcing.
3. Validated blending and filling equipment.
4. Segregated cylinder operations.
5. Accurate concentration testing.
6. Qualified valves and regulators.
7. Medical-gas regulatory compliance.
8. Hospital distribution.
9. Emergency replenishment capability.
10. Product liability controls.

Helium availability is especially important. A supplier may hold regulatory approval and still fail commercially if it cannot maintain inventory during supply disruptions. Long-term helium procurement contracts, diversified sourcing, cylinder-turn management, and regional storage can be more valuable than a narrow composition patent.

What is the revenue exposure for oxygen helium mixture 20/80?

Revenue exposure is generally modest compared with major inhaled drugs, biologics, or chronic respiratory products. The opportunity is concentrated in institutional and specialty channels rather than mass retail sales.

Potential revenue streams include:

• Gas sales by cylinder or volume
• Cylinder rental and service
• Regulators and delivery equipment
• Disposable masks and tubing
• Hospital supply contracts
• Emergency transport kits
• Technical service
• Training and implementation
• Monitoring and inventory software

Margin expansion is more likely from bundled systems and recurring service than from the gas commodity itself. A supplier selling only cylinders is exposed to price competition. A supplier controlling delivery equipment, clinical support, and hospital logistics can capture higher account value.

Key Takeaways

• Oxygen helium mixture 20/80 is a medical gas, not a conventional excipient-containing drug formulation.
• The mixture contains 20% oxygen and 80% helium and has a high helium fraction with limited oxygen reserve.
• Composition-based patent protection is likely limited because oxygen, helium, and heliox mixtures are established technologies.
• The most valuable IP opportunities involve regulators, ventilators, flow compensation, monitoring, valves, and patient interfaces.
• FDA status is product-specific and depends on labeling, manufacturing, listing, and intended medical use.
• Orange Book and Paragraph IV strategies are less central than for conventional small-molecule drugs.
• Commercial differentiation should focus on delivery systems, cylinder logistics, hospital contracts, and clinical implementation.
• Helium procurement and medical-gas distribution are major entry barriers.
• Licensing value is likely to reside in integrated respiratory systems rather than in the 20/80 gas composition alone.

FAQs

Is 20/80 heliox the same as room air?

No. Room air contains approximately 20.9% oxygen and mostly nitrogen. A 20/80 heliox mixture replaces most nitrogen with helium and contains slightly less oxygen than room air.

Can 20/80 heliox be used with a standard oxygen regulator?

Not automatically. Helium changes gas density and can affect flow-meter and regulator accuracy. Equipment should be validated or specifically calibrated for helium-containing mixtures.

Does 20/80 heliox require a prescription?

Medical-use status depends on the jurisdiction, product labeling, and intended use. In the United States, a product marketed to treat or mitigate disease is subject to medical-gas drug requirements.

Is heliox eligible for orphan-drug exclusivity?

The mixture does not receive orphan-drug exclusivity automatically. Eligibility would depend on a specific sponsor, indication, regulatory designation, and approved product.

What is the strongest commercial patent opportunity in heliox?

The strongest opportunity is generally a helium-compatible respiratory delivery platform that integrates flow compensation, oxygen monitoring, alarms, and validated clinical use. A patent covering only the 20/80 composition would likely provide weaker differentiation.

References

1. U.S. Food and Drug Administration. (2016). Medical gas regulation: Final rule. Federal Register, 81 Fed. Reg. 81685.

2. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary: Medical gas and gas quality standards. USP-NF.

4. U.S. Food and Drug Administration. (2024). Current good manufacturing practice and quality system guidance for medical gases. Center for Drug Evaluation and Research.